Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
36.20
+0.66 (1.84%)
At close: Oct 15, 2025, 4:00 PM EDT
35.93
-0.27 (-0.75%)
After-hours: Oct 15, 2025, 4:00 PM EDT
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $193.00K in the quarter ending June 30, 2025, a decrease of -89.64%. This brings the company's revenue in the last twelve months to $4.85M, up 17.87% year-over-year. In the year 2024, Dianthus Therapeutics had annual revenue of $6.24M with 120.63% growth.
Revenue (ttm)
$4.85M
Revenue Growth
+17.87%
P/S Ratio
258.64
Revenue / Employee
$62,231
Employees
78
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDNTH News
- 13 days ago - Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - GlobeNewsWire
- 4 weeks ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call - Seeking Alpha
- 5 weeks ago - Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire